Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Total revenues	$ 48,663	$ 32,127
Cost of revenues:
Total cost of revenues	20,680	15,963
Gross profit	27,983	16,164
Operating expenses:
Research and development	27,822	21,448
Sales and marketing	6,671	5,239
General and administrative	22,133	13,389
Total operating expenses	56,626	40,076
Loss from operations	(28,643)	(23,912)
Other (expense) income:
Loss on equity investments		(1,781)
Change in fair value	(6,164)	24,824
Interest income	328	420
Total other (expense) income	(5,836)	23,463
Loss before income taxes	(34,479)	(449)
Income tax (benefit) expense	(28)	74
Net loss	(34,451)	(523)
Net loss attributable to noncontrolling interest	(11)	(494)
Net loss attributable to Schrödinger common and limited common stockholders	$ (34,440)	$ (29)
Net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted:	$ (0.48)	$ 0.00
Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted:	71,050,432	70,071,625
Software Products and Services
Revenues:
Total revenues	$ 33,081	$ 26,340
Cost of revenues:
Total cost of revenues	7,511	5,906
Drug Discovery
Revenues:
Total revenues	15,582	5,787
Cost of revenues:
Total cost of revenues	$ 13,169	$ 10,057